Active	Status	Sponsor type	Region	Phase	Filter
11 Active 2 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Palladini, Giovanni
EMN22, NCT04131309 / 2018-004333-33: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	Active, not recruiting	2	40	Europe	Daratumumab, Bortezomib Injection, velcade, Dexamethasone oral tablet	Stichting European Myeloma Network, Janssen Pharmaceutica	Light Chain (AL) Amyloidosis, Stage 3B	01/25	01/25
EMN27, NCT04617925 / 2020-004001-32: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis	Active, not recruiting	2	35	Europe	Belantamab mafodotin	Stichting European Myeloma Network, GlaxoSmithKline	AL Amyloidosis	07/25	07/25
ZN-d5-003, NCT05199337 / 2021-003008-42: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Completed	1/2	18	Europe, US, RoW	ZN-d5, Study Drug	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc	Amyloidosis, AL Amyloidosis	02/24	02/24
ProDigALIty, NCT06383143: Promoting Diagnosis and Management of AL in Italy	Recruiting	N/A	760	Europe	no intervention	Fondazione IRCCS Policlinico San Matteo di Pavia	AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance	05/25	05/25
EUREKA, NCT06205953: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis	Recruiting	N/A	400	Europe, RoW		Fondazione IRCCS Policlinico San Matteo di Pavia	AL Amyloidosis	06/26	06/26
NCT04392960: Novel Imaging Tools in Newly-diagnosed Patients with Cardiac AL Amyloidosis	Recruiting	N/A	69	Europe	[18F]Florbetaben	Fondazione IRCCS Policlinico San Matteo di Pavia	AL Amyloidosis	02/25	02/25
ReAL, NCT04839003: A Registry of AL Amyloidosis	Recruiting	N/A	5000	Europe		Fondazione IRCCS Policlinico San Matteo di Pavia	AL Amyloidosis	05/25	05/25
ITALY, NCT04563286: Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis	Recruiting	N/A	250	Europe	questionnaire on life quality	University of Messina, Fondazione Toscana Gabriele Monasterio, University of Pavia, Università degli Studi di Ferrara, Careggi Hospital	Transthyretin Amyloidosis	04/22	06/22
Esposito, Ciro
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -	Terminated	3	667	Europe, Japan, US, RoW	Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC	Autosomal Dominant Polycystic Kidney, ADPKD	08/23	08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	404	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics, Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	12/26	12/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Novartis Pharmaceuticals	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26
Mazzucchelli, Iolanda
No trials found